Data from: Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis

Objectives: We aimed to characterise the prevalence and burden of HAND and assess associated factors in the global population with HIV. Methods: We searched PubMed and Embase for cross-sectional or cohort studies reporting the prevalence of HAND or its subtypes in HIV-infected adult populations from Jan 1, 1996, to May 15, 2020, without language restrictions. Two reviewers independently undertook the study selection, data extraction, and quality assessment. We estimated pooled prevalence of HAND by a random effects model and evaluated its overall burden worldwide. Results: Of 5588 records identified, we included 123 studies involving 35513 participants from 32 countries. The overall prevalence of HAND was 42·6% (95% CI: 39·7-45·5), and did not differ with respect to diagnostic criteria used. The prevalence of asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HAD) were 23·5% (20·3-26·8), 13·3% (10·6-16·3) and 5·0% (3·5-6·8) according to the Frascati criteria, respectively. The prevalence of HAND was significantly associated with the level of CD4 nadir, with a prevalence of HAND higher in low CD4 nadir groups (mean/median CD4 nadir